Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

 

 

 

The primary research interest of Erik is the genetic architecture of cardiovascular disease and associated conditions. He is also interested in understanding the role of circulating biomarkers (such as proteins or metabolites) in pathways linking genetics and disease. Erik is involved in several genetic consortia, such as MAGIC (Meta-Analysis of Glucose and Insulin-related traits Consortium), GIANT (Genetic Investigation of ANthropometric Traits), GENESIS (GENEticS of Insulin Sensitivity), EchoGen, and Global Lipids Genetics Consortium. He is currently spearheading a MAGIC project aiming at characterizing recently discovered loci associated with fasting glucose and insulin by using more detailed glucometabolic phenotypes derived from euglycemic clamps, insulin suppression tests, proinsulin and 3-point oral glucose tolerance tests. Also, he is currently putting a lot of effort in the GIANT collaboration, especially in the work with BMI. In ENGAGE, he is one of the coordinators of a flagship project called ‘Large-scale genotyping of selected causal variants’. The purpose of this project is to genotype a limited number of SNP variants in all cohorts that were listed in the application as having DNA available to ENGAGE. The scientific aims are to obtain very large-scale data on a limited number of SNPs for estimations of population effect, joint effects of genes and environment, but also to develop infrastructure to support large-scale genotyping efforts and to develop informatics and analytical pipelines for such data that will facilitate future data aggregation.

Webpage: www.ingelsson.org


 

 

ENGAGE April 2009
ENGAGE Young Investigator

Erik Ingelsson



Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden